Chamberlin Free Public Library Catalog

Bad blood : (Record no. 63235)

MARC details
000 -LEADER
fixed length control field 03146cam a2200385 i 4500
001 - CONTROL NUMBER
control field on1029779381
003 - CONTROL NUMBER IDENTIFIER
control field OCoLC
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20221230155440.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 180316t20182018nyu b 001 0 eng
010 ## - LIBRARY OF CONGRESS CONTROL NUMBER
LC control number 2018000263
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781524731656
Qualifying information hardcover
International Standard Book Number 152473165X
Qualifying information hardcover
035 ## - SYSTEM CONTROL NUMBER
System control number (OCoLC)on1029779381
037 ## - SOURCE OF ACQUISITION
Source of stock number/acquisition Random House Inc, Attn Order Entry 400 Hahn rd, Westminster, MD, USA, 21157
Note SAN 201-3975
040 ## - CATALOGING SOURCE
Original cataloging agency DLC
Language of cataloging eng
Description conventions rda
Transcribing agency DLC
Modifying agency OCLCO
-- SSH
-- OCLCF
-- JSE
-- FEM
-- QQ3
-- JTH
-- YDX
-- CZA
-- OCLCO
-- JQM
042 ## - AUTHENTICATION CODE
Authentication code pcc
043 ## - GEOGRAPHIC AREA CODE
Geographic area code n-us---
050 00 - LIBRARY OF CONGRESS CALL NUMBER
Classification number HD9995.H423
Item number U627 2018
082 00 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 338.7/681761
Edition number 23
084 ## - OTHER CLASSIFICATION NUMBER
Classification number BUS025000
-- BUS027000
-- TEC059000
Source of number bisacsh
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Carreyrou, John,
Relator term author.
9 (RLIN) 128457
245 10 - TITLE STATEMENT
Title Bad blood :
Remainder of title secrets and lies in a Silicon Valley startup /
250 ## - EDITION STATEMENT
Edition statement First edition.
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Place of publication, distribution, etc New York :
Name of publisher, distributor, etc Alfred A. Knopf,
Date of publication, distribution, etc 2018.
Date of publication, distribution, etc �2018
300 ## - PHYSICAL DESCRIPTION
Extent x, 339 pages ;
Dimensions 25 cm
504 ## - BIBLIOGRAPHY, ETC. NOTE
Bibliography, etc Includes bibliographical references and index.
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note A purposeful life -- The gluebot -- Apple envy -- Goodbye East Paly -- The childhood neighbor -- Sunny -- Dr. J -- The miniLab -- The wellness play -- "Who is LTC Shoemaker?" -- Lighting a Fuisz -- Ian Gibbons -- Chiat\day -- Going live -- Unicorn -- The grandson -- Fame -- The hippocratic oath -- The tip -- The ambush -- Trade secrets -- La mattanza -- Damage control -- The empress has no clothes -- Epilogue.
520 ## - SUMMARY, ETC.
Summary, etc "The full inside story of the breathtaking rise and shocking collapse of Theranos--the Enron of Silicon Valley--by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in an early fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at the Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--
610 20 - SUBJECT ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element Theranos (Firm)
General subdivision History.
9 (RLIN) 128458
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Hematologic equipment industry
Geographic subdivision United States.
9 (RLIN) 128459
Topical term or geographic name as entry element Fraud
Geographic subdivision United States.
9 (RLIN) 128460
655 #7 - INDEX TERM--GENRE/FORM
Genre/form data or focus term History.
Source of term fast
9 (RLIN) 128461
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme Dewey Decimal Classification
Koha item type NF
Holdings
Withdrawn status Lost status Collection code Home library Current library Shelving location Date acquired Source of acquisition Full call number Barcode Number Koha item type
    Nonfiction Chamberlin Free Public Library Chamberlin Free Public Library Nonfiction 12/28/2022 Gift. 338.7 CAR 34480000593289 NF